Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Gastrointestinal Stromal Tumor

Recruiting

2

Start Date 08/12/2021

Age of Trial (yrs) 3.7

Gleevec-resistant

SDH-directed

HIF-2a inhibitor

Specifically GIST plus other cancers

6482-015 MK-6482-015 ( Other Identifier: Merck ) PT2977 ( Other Identifier: Former name ) jRCT2011220024 ( Registry Identifier: Japan Registry of Clinical Trials (jRCT) ) 2023-504853-11( Registry Identifier: EU CT ) 2020-005028-13 ( EudraCT Number )

Merck Sharp & Dohme LLC

1-888-577-8839 Trialsites@msd.com

Oral

Inclusion Criteria: Partial

For Cohort C participants with GIST (wt):

Has documented histopathological diagnosis of GIST.
Local test report documenting the absence of sensitizing mutations in both platelet derived growth factor receptor alpha (PDGFRA) and receptor tyrosine kinase (c-KIT).
Has locally advanced or metastatic disease that is not amenable to surgery or curative intent treatment.